Resiliency Self Directed Recovery
Added: Aug 14, 2015 7:46 am
Notice of Intent to Sole Source:Pursuant to the authority of FAR 13.106-1(b)(1)(i), the Contracting Officer may solicit from one source if the Contracting Officer determines that the circumstances of the contract action deem only one source is reasonably available. The Department of Health and Human Services (DHHS), Program Support Center (PSC), Acquisition Management Services (AMS) on behalf of PSC, Substance Abuse and Mental Health Services Administration (SAMHSA) intends to sole source to:Faces & Voices of Recovery1010 Vermont Ave NW Suite 618 Washington, DC 20005-4941Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Office of the Director, Office of Consumer Affairs (OCA) seeks to train support specialists, coaches, and people in recovery to educate the media, the public, and policymakers about the benefits of using a peer support recovery approach to address and mitigate homelessness issues through a series of webinars. The webinars will focus on best practices and program outcomes among successful community recovery centers across the nation as it relates to housing issues and the homeless population.The Substance Abuse and Mental Health Services Administration (SAMHSA) is cognizant that the behavioral health field will experience a workforce gap created by the increase demand for behavioral health specialists in all categories as a result of the passage of the Affordable Care Act (ACA) and the Mental Health Parity and Addiction Equity Act (MHPAEA). Moreover, the behavioral health workforce will also experience an exodus from the marketplace of thousands of specialists due to retirement. In order to fill this service gap, SAMHSA is looking to create an interest in medical and non-medical professions within the behavioral health field. The population focus is students entering college who have yet to declare a major and those enrolled in the social sciences. Faces & Voices of Recovery has the experience, knowledge and materials to successfully complete this requirement. Faces & Voices of Recovery (FAVOR) are the owners of the research and data used in the development of outreach materials and trainings in changing the public's perception of what is recovery. FAVOR works with treatment- and recovery-oriented individuals and organizations throughout the country to provide a unified and cohesive face and voice of consumers of recovery services to reach out and educate policymakers, health care providers and insurers, the justice system and social service organizations about the need for available and effective treatment and recovery services for those in need.FAVOR has a strong consumer and community-based recovery network which helps to increase the number of individuals reaching out to educate others about substance use and mental disorders, treatment and long-term recovery, based on their personal recovery experience. In addition, FAVOR continues to encourage and empower its membership to be aware of and understand the need to expand the Nation's treatment capacity and to reduce barriers to treatment - including the barriers of those who are homeless and in need of recovery.This is not a solicitation for competitive proposal. No solicitation document is available. All responsible sources that have determined that they can provide the same services may submit product information and a capabilities statement addressing their specific abilities regarding this requirement. The email subject line must reference SAM156698. All responses are due by August 20, 2015, 8:00 AM Eastern Time and can be sent to Flora Gomes at flora.gomes@psc.hhs.gov. A determination by the Government not to compete this proposed contract base upon responses to this notice is solely within the discretion of the government.
SAM156698 Department of Health and Human Services Program Support Center
8/14/15, 7:46 AM Tobacco Cessation Services
Added: Sep 10, 2009 7:43 pm
This is a combined synopsis/solicitation for commercial supplies prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested and a written solicitation will not be issued. (ii) Solicitation FA4877-09-M-R012 is issued as a request for quotation (RFQ).(iii) This solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-36, Defense Circular Number 20090825 and Air Force Acquisition Circular 2009-0803 (iv) This procurement is being issued as full and open competition. The NAICS code for this requirement is 813212.(v) The contractor shall provide all personnel, labor, transportation, supervision, materials, equipment, and management: to provide the following: Perform telephone support/counesling for the 355th medical sqaudron smoking cessation program, Davis-Monthan Air Force Base (DMAFB), AZ. Period of performance shall be from Oct 1 2009 through Sep 30 2010 (all work shall be done in accordance with attached PWS).The provision at 52.212-1--Instructions to Offerors -- Commercial, applies to this acquisition. (ix) 52.212-2--Evaluation -- Commercial Items applies. Quotes will be evaluated on the lowest price technically acceptable, and the quote that will yield the best value to the Government. (x) Offerors must include a completed copy of the provision at, 52.204-8-- Annual Representations and Certifications and submit with its offer. (xi) Clause 52.204-9--Personal Identity Verification of Contractor Personnel - contractor shall comply with agency personal identity verification procedures identified in the contract that implement Homeland Security Presidential Directive-12 (HSPD-12), Office of Management and Budget (OMB) guidance M-05-24, and Federal Information Processing Standards Publication (FIPS PUB) Number 201. (xii) Clause 52.212-4--Contract Terms and Conditions -- Commercial Items, applies to this acquisition. (xiii) 52.212-5--Contract Terms and Conditions Required To Implement Statutes Or Executive Orders--Commercial Items to include clauses 52.222-3--Convict Labor 52.222-19--Child Labor-Cooperation with Authorities and Remedies 52.222-21, Prohibition of Segregated Facilities 52.222-26--Equal Opportunity 52.222-36--Affirmative Action for Workers with Disabilities 52.225-13--Restriction on Certain Foreign Purchases 52.204-7--Central Contractor Registration, 52.209-5--Certification Regarding Debarment, Suspension, Proposed Debarment, and Other Responsibility Matters, 52.209-6--Protecting the Governments Interest When Subcontracting with Contractors Debarred, Suspended, or Proposed for Debarment, 52.232-33--Payment by Electronic Funds Transfer--Central Contractor Registration, 52.237-3--Continuity of Services, 52.247-34--F.O.B.- Destination, 52.222-19--Child Labor-Cooperation with Authorities and Remedies, 52.222-41--Service Contract Act of 1965, 52.222-42--Statement of Equivalent Rates for Federal Hires 52.222-37-- Employment Reports on Special Disabled Veterans, Veterans of the Vietnam Era and Other Eligible Veterans, 52.232-33--Payment by Electronic Funds Transfer-Central Contractor Registration, 52.246-4--Inspection of Services -- Fixed-Price, 252.232-7003--Electronic Submission of Payment Requests, 5352.201-9101--AF Ombudsman clause- ACC Ombudsman follows: Mr. Eric Thaxton, 129 Andrews Street, Langley AFB VA 23665, phone: (757) 764-5372, fax: (757) 764-4400, email: eric.thaxton@langley.af.mil., Clause DM001 - If applicable, the Arizona/City Business Use Fee has been included in the unit price.Proposals shall be due to the 355th Contracting Squadron, 3180 S. Craycroft Rd. Davis-Monthan AFB, AZ 85707, via fax or email by Monday, 14 August 2009 at 4:00pm PST. Point of Contact is AMN Branden Reagan at e-mail branden.reagan @dm.af.mil, Phone (520) 228-5461, or Fax (520) 228-5284.
FA4877-09-M-R012-SmokingCessation_reagan Department of the Air Force Air Combat Command
9/10/09, 7:43 PM Procurement is to analyze induced pluripotent stem cells (iPSCs)
Added: May 15, 2018 8:17 am
COMBINED SYNOPSIS / SOLICITATIONSOLICITATION NUMBER: 75N92018Q0162(i) "This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued."(ii) The solicitation number is 75N92018Q0162 and the solicitation is being posted as a request for proposal (RFP) to(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-97, January 24, 2018.(iv) This is not a set-aside, the associated NAICS Codes: 813212, Voluntary Health Organizations and small business size standard is $27.5M. The acquisition is being conducted in accordance with the procedures of FAR Part 12 and FAR Part 13. All responsible offerors may submit a proposal, which if timely received, shall be considered by the agency. Offers are due by 7:30 A.M. Eastern Time (EST) on May 22, 2018. Responses must be submitted via the FedConnect webportal (www.fedconnect.net). Potential Offerors do not need to register to view a notice; however, in order to submit questions and/or response to this Notice, an account will need to be established. (v) Background:The National Institutes of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Human Genome Research Institute (NHGRI), mission has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. A critical part of the NHGRI mission continues to be the study of the ethical, legal and social implications (ELSI) of genome research. The Medical Genomics and Metabolic Genetics Branch/Molecular Genetics Section Investigators use a broad range of tools to understand how health and disease are related to genetic, genomic and metabolic variation. Investigators study a broad spectrum of disorders, from common diseases associated with common variants to the rarest diseases associated with uncommon, sometimes unique variants. Scientific Investigators sometimes study disorders that are not inherited at all, which are due to somatic mosaicism-a difference in genetic composition among cells in an individual. Additionally, also study how the genome influences normal metabolic processes.MGMGB investigators apply tools ranging from high-throughput biology to clinical and animal research. A unifying theme in research is that the human is the most complex, fascinating and important system in which one can study the effects of heritable variation. For twenty years, NHGRI have been engaged in a large collaborative study entitled FUSION (Finland United States Investigation of NIDDM), in which more than 30,000 individuals with type 2 diabetes (T2D) (and suitable controls) from Finland are being studied. To achieve the objectives of the diabetes research the National Institute of Human Genome Research (NHGRI), Medical Genomics and Metabolic Genetics Branch (MGMGB) are initiating a translational research program extending the genetic association of T2D related genes to the functional analysis of these genes and the effects of the genetic background of normal vs. T2D subjects in tissues relevant to T2D. Towards this goal the FUSION project has collected skeletal muscle and adipose samples from ~100 normal glucose tolerant, ~100 impaired glucose response and 78 newly diagnosed T2D subject prior to medication. This allows the functional analysis of gene expression correlation with disease state and genetic background of the subjects.Purpose and Objectives:The purpose of this procurement is to analyze induced pluripotent stem cells (iPSCs) throughout the differentiation stages to mature beta cells and functionally characterize the mature beta cell product insulin response to glucose to advance the study of the functional basis of genetic variants associated with type 2 diabetes (T2D). Also, to investigate differential genetic influence on pancreatic beta cell on the genetic background of our Finnish T2D cohort we aim to differentiate iPSC cell lines derived from the FUSION Tissue Biopsy Study subject fibroblasts into mature beta cell lineages to assess the glucose stimulated insulin secretion response of normal glucose tolerant versus T2D subjects.The foresight towards the advent of induced pluripotent stem cell (iPSC) technology the FUSION Study also collected skin biopsies with which generated epidermal fibroblast cell cultures as a resource. Implementation of iPSC protocols allows for the dedifferentiation of fibroblasts into a pluripotent state of cells which in turn can be differentiated into different lineages of tissues of interest in T2D otherwise unobtainable from human subjects, such as, such as but not restricted to pancreatic beta cells, representing pancreatic islets; adipocytes, representing fat tissue; hepatocytes, representing liver tissue, myocytes, representing skeletal muscle, and neuronal cells. The capability of differentiating iPSCs into T2D relevant tissue types FUSION investigators can perform functional analysis of genes associated with T2D that are characteristic of the tissues involved in the disease examining the differential effect of the genetic make-up of the original subjects on the function of the associated gene in that particular tissue type. This allows for the functional analysis of genes responsible for T2D in the context of gene networks and tissue environment that was not achievable prior to iPSC differentiation. In addition, this valuable resource enables the generation of important resources for the evaluation of potential therapeutics in model cell lines of relevant tissues to the treatment of T2D.Procurement:1. To provide Beta Cell Differentiation and Cell Assay, Twelve (12) Lines.Anticipated Period of Performance:Base Year: May 2018 to May 2019Option 1: May 2019 to May 2020Contractor' Requirement:• The Contractor shall present sufficient capacity to differentiate 12 iPSCcell lines to pancreatic beta cell lineage in a reproducible automated protocol according to prescribed study with one year.• The Contractor shall be proficient in differentiation of iPSC to beta cellsin order to complete differentiation in 40 days or less generating ≥ 400,000 cells per time point.• The Contractor shall monitor the differentiation process with sufficientbiomarker analyses to verify interim stage identity throughout the seven stages to mature beta cells and provide 400,000 cells at no less than 4-time points throughout the differentiation time course for assessment of differentiation efficiency by single cell RNA sequencing (scRNA-Seq).• The Contractor shall be proficient in performing automated glucosestimulated insulin secretion (GSIS) assay upon mature beta cell differentiation providing ≥400,000 cells at each of four-time points (0, 30, 60, and 120 minutes) including collection of experimental supernatant for appropriate insulin measurement.• The Contractor shall be proficient at dissociation of mature beta cellorganoids at each time point of collection and capable of single cell cryopreservation for transfer to the laboratory at NIH for comprehensive genomic and epigenomic analyses.• The Contractor shall generate multiple pools of mature beta cells for eachdifferentiated cell line to achieve the number of cells required for analysis in a robust reproducible process for analysis.• The Contractor shall provide documentation of the process of generatingthe mature beta cell lines as well as the raw data supporting the process upon request.• The Contractor shall provide monthly written reports and quarterlyConference call updates throughout the generation of the mature beta cells from iPSC lines and performance of the GSIS assay.Deliverables:The Contractor shall deliver the following:• The Contractor shall deliver Cells within ~6-8 months post execution of agreement and delivery of starting material.• The Contractor shall deliver iPS cell lines with master bank from up to 2 polyclonal pools (6 vials per pool). Expansion to larger working banks possible. • Shall deliver Protocol for iPS cell line recovery;• Shall deliver Certificate of Analysis which will be made available and will include results from mycoplasma and sterility tests, identity and karyotype data, plutipotency expression profile and differentiation capacity. Raw data can be made available upon request;• Shall deliver monthly written progress report; and• Shall deliver quarterly phone updates.EVALUATION OF PROPOSALS:The Government will evaluate proposals that are determined technically acceptable in accordance with the Technical Evaluation factors. The Government intends to award a single contract from this solicitation. The Government reserves the right not to award a contract.Evaluation of Proposals: The Government reserves the right to make an award without discussions based solely upon initial proposals.Price (This will be Firm-Fixed Price): An evaluation of the offeror's price proposal will be made to determine if proposed prices are realistic for the work to be performed, reflect a clear understanding of the requirements, and are consistent with the technical proposal. Reasonableness determinations will be made by determining if competition exists, by comparing proposed prices with established commercial or GSA price schedules (if applicable), and/or by comparing proposed prices with the Independent Government Cost Estimate (IGCE).EVALUATION FACTORS:The evaluation will be based on the following:1. Must be able to present sufficient capacity to differentiate 12 iPSC cell lines to pancreatic beta cell lineage in a reproducible automated protocol according to prescribed study with one year.2. Lowest price technically acceptable (LPTA).vi. The FAR Provision 52.212-1, Instructions to Offerors -- Commercial, applies to thisacquisition and is hereby incorporated by reference. All Federal Acquisition Regulations (FAR) clauses may be viewed at http://acquisition.gov/comp/far/index.html.The proposal must reference the RFP Number: 75N92018Q0162. All responsible offerors may submit a proposal, which if timely received, shall be considered by the agency.All proposals shall contain the following:1. Name of Contracting Organization;2. Solicitation number;3. Contract Type;4. Total Contract Value and Discounts;5. Description of Requirement;6. North American Industry Classification System (NAICS) Code; and7. DUNS, TIN or EIN Number.ix. In accordance to FAR clause 52.212-2, Evaluation - Commercial Itemsx. In accordance with FAR Clause 52.212-3, Offeror Representations and Certifications - Commercial Items, offerors must complete annual representations and certifications on- line at https://www.sam.gov/portal/public/SAM/.xi. FAR clause 52.212-4, Contract Terms and Conditions - Commercial Items applies to this acquisition.xii. FAR clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items applies to this Acquisition. Additional FAR Clauses include:FAR clause 52.204-10, Reporting Executive Compensation and First-Tier SubcontractAwards (JUL2013) (Pub.L. 109-282) (31 U.S.C. 6101 note).FAR clause 52.223-18, Encouraging Contractor Policies to Ban Text Messaging whileDriving (AUG2011).FAR clause 52.225-13, Restrictions on Certain Foreign Purchases (JUN 2008) (E.O.'s,proclamations, and statutes administered by the Office of Foreign Assets Control of theDepartment of the Treasury).FAR clause 52.232-33, Payment by Electronic Funds Transfer-System for AwardManagement (JUL2013) (31 U.S.C. 3332).xiii. All responses must be received by May 22, 2018, 7:30 a.m. Eastern time. Responses must be submitted via the FedConnect webportal (www.fedconnect.net). Potential Offerors do not need to register to view a notice; however, in order to submit questions and/or response to this Notice, an account will need to be established. Should you require a waiver not to use FedConnect, please contact the Contracting Office: National, Heart, Lung and Blood Institute, Section 3, Branch B, Office of Acquisitions, Office of Management, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell, Contracting Officer (maxwelld@nih.gov). Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency and include the following:1. Name of Contracting Organization;2. Solicitation number;3. Contract Type;4. Total Contract Value and Discounts;5. Description of Requirement;6. North American Industry Classification System (NAICS) Code; and7. DUNS, TIN or EIN Number.xv. All responsible offerors may submit a proposal, which if timely received, shall be considered by the agency. Offers are due by 7:30 A.M. Eastern Time (EST) on May 22, 2018. Dorothy Maxwell, Contracting Officer can be reached at (301) 827-7729 regarding any questions regarding Solicitation Number: 75N92018Q0162.Quotations shall not be deemed received by the Government until the quotation is entered into the e-mail address inbox set forth above. Faxed proposals will NOT be accepted.Offerors must complete annual representations and certifications on-line at https://www.sam.gov/portal/public/SAM/.
75N92018Q0162 Department of Health and Human Services National Institutes of Health
5/15/18, 8:17 AM Annual ISMP Subscription Medication Safety Alerts "Acute Care Newsletter" 4/1/16-4/1/17
Added: Mar 17, 2016 4:30 pm
The VA Great Lakes Acquisition Center (GLAC) intends to negotiate a sole source contract with the Institute for Safe Medication Practices of Horsham, PA to provide the newsletter Acute Care; access to a national proprietary database containing information on medication and device errors, adverse drug reactions, and practical prevention strategies; and educational information for pharmacists at the Edward Hines VA Hospital in Hines, IL.
This is a contract for a base year and four 12 month option years. This procurement is being conducted in accordance FAR 13.106-1(b), exclusive licensing agreements. The contract is firm fixed price, and the NAICS Code is 813212 with a size standard of $27.5 Million.
This Notice of Intent is not a request for competitive quotes or proposals. No solicitation documents are available and telephone requests will not be honored. However, if a firm believes it can meet the requirements it must furnish information about its products and services, as well as references from other customers who are using these products to the Contract Specialist within ten (10) calendar days from the date of publication of this synopsis. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to comply with the above requirements. Information must be mailed or hand-carried to:
Michael Sands
Great Lakes Acquisition Center (GLAC) - Southern Tier
3001 Green Bay Road
Building 1, Room 315
North Chicago, IL 60064-3048
Information may also be sent via fax to (224) 610-3269. Responses received will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the Government. If no responses are received, the GLAC will proceed with the sole source negotiation with the Institute for Safe Medication Practices.
VA69D16N0580 Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12
3/17/16, 4:30 PM